EQS-News

Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership 28.03.2023 / 11:02 CET/CEST The issuer is solely responsible for the content of this announcement. 8-YEAR EXTENSION AND EXPANSION OF ONGOING COLLABORATION TO DEVELOP A BROADENED PROGRAMME PIPELINE IN NEURODEGENERATIVE DISEASES PARTNERSHIP LEVERAGES EVOTEC’S PRECISION MEDICINE PLATFORMS FINANICAL TERMS INCLUDE $ 50 M UPFRONT PAYMENT, PERFORMANCE MILESTONES AND TIERED ROYALTIES ON PRODUCT SALES

Hamburg, Germany, 28 March 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb (NYSE: BMY), originally signed in 2016. The initial partnership proved highly productive in generating a promising pipeline of discovery to clinical-stage programmes. Based on this success, Bristol Myers Squibb and Evotec extend and expand this partnership for additional 8 years with the goal to further broaden and deepen the strategic alliance.

Evotec and Bristol Myers Squibb (formerly “Celgene”) initiated the collaboration in 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of patients’ symptoms and there is a significant unmet medical need for therapies that slow down or reverse disease progression in the field of neurodegenerative diseases.

This partnership pursues an innovative approach to the discovery and development of novel medicines by leveraging several of Evotec’s modality-agnostic precision medicine platforms. The partnership has already been successful in generating a pipeline of discovery and pre-clinical-stage programmes. A first programme, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021, following the successful filing of an IND application with the FDA and has proceeded into the clinical Phase I.